Talamo Joseph 4

What Happened Joseph Talamo, Chief Financial Officer of Intensity Therapeutics (INTS), acquired 1,093 shares on June 30, 2026 through the issuer's Employee Stock Purchase Plan (ESPP). The shares were purchased at $3.48 per share for a total reported value of $3,809. This was an acquisition (purchase), which is generally a more informative signal than routine sales.

Key Details

• Transaction date and price: June 30, 2026 — 1,093 shares at $3.48/share (total $3,809).
• Method: Purchased under the Issuer’s Amended and Restated 2024 ESPP; transaction reported as exempt under Rule 16b-3(c) and 16b-3(d).
• Purchase price detail: ESPP purchase price was 85% of the closing price on June 30, 2026 (per filing footnote).
• Reverse split adjustment: All reported amounts were adjusted for a 1-for-25 reverse stock split effective February 18, 2026.
• Shares owned after transaction: Not specified in the information provided on this Form 4.
• Filing timeliness: Form 4 was filed on July 1, 2026 for a June 30, 2026 transaction (no late filing indicated in the provided data).

Context This was an ESPP purchase (employee purchase at a discount), not an option exercise or open-market trade. ESPP purchases are common compensation/benefit transactions and do not by themselves indicate the insider's broader market view. The reported numbers reflect post–reverse-split adjustments.